Stem Cells Translational Medicine (Aug 2017)
Concise Review: Developing Best‐Practice Models for the Therapeutic Use of Extracellular Vesicles
- Agnes T. Reiner,
- Kenneth W. Witwer,
- Bas W.M. van Balkom,
- Joel de Beer,
- Chaya Brodie,
- Randolph L. Corteling,
- Susanne Gabrielsson,
- Mario Gimona,
- Ahmed G. Ibrahim,
- Dominique de Kleijn,
- Charles P. Lai,
- Jan Lötvall,
- Hernando A. del Portillo,
- Ilona G. Reischl,
- Milad Riazifar,
- Carlos Salomon,
- Hidetoshi Tahara,
- Wei Seong Toh,
- Marca H.M. Wauben,
- Vicky K. Yang,
- Yijun Yang,
- Ronne Wee Yeh Yeo,
- Hang Yin,
- Bernd Giebel,
- Eva Rohde,
- Sai Kiang Lim
Affiliations
- Agnes T. Reiner
- BioSensor Technologies, AIT Austrian Institute of TechnologyVienna Austria
- Kenneth W. Witwer
- Departments of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimore Maryland USA
- Bas W.M. van Balkom
- Department of Nephrology and HypertensionUniversity Medical Center UtrechtUtrechtThe Netherlands
- Joel de Beer
- Anjarium Biosciences AG Zollikon Switzerland
- Chaya Brodie
- Department of NeurosurgeryHenry Ford HospitalDetroit Michigan USA
- Randolph L. Corteling
- ReNeuron Group, Pencoed United Kingdom
- Susanne Gabrielsson
- Department of MedicineUnit for Immunology and Allergy, Karolinska InstituteStockholmSweden
- Mario Gimona
- Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI‐TReCS), Paracelsus Medical University (PMU)Salzburg Austria
- Ahmed G. Ibrahim
- Capricor TherapeuticsLos AngelesCalifornia USA
- Dominique de Kleijn
- Dept. of Vascular Surgery & CardiologyUtrecht UniversityUtrecht The Netherlands
- Charles P. Lai
- Institute of Biomedical EngineeringNational Tsing Hua UniversityHsinchu Taiwan Republic of China
- Jan Lötvall
- Krefting Research Centre, Institute of Medicine, The Sahlgrenska Academy, Gothenburg UniversityGothenburg Sweden
- Hernando A. del Portillo
- ICREA at ISGlobal Barcelona Institute for Global Health, Ctr. Int. Health Res. (CRESIB), Hospital Clínic, University of BarcelonaBarcelona Spain
- Ilona G. Reischl
- Federal Office for Safety in Health Care, Institute SurveillanceVienna Austria
- Milad Riazifar
- Department of Pharmaceutical SciencesUniversity of CaliforniaIrvine California USA
- Carlos Salomon
- Centre for Clinical Research, Royal Brisbane and Women's Hospital, The University of QueenslandBrisbane Australia
- Hidetoshi Tahara
- Department of Cellular and Molecular BiologyInstitute of Biomedical & Health Sciences, Hiroshima UniversityHiroshima Japan
- Wei Seong Toh
- Faculty of DentistryNational University of Singapore Singapore
- Marca H.M. Wauben
- Department of Biochemistry and Cell BiologyFaculty of Veterinary Medicine, Utrecht UniversityUtrecht The Netherlands
- Vicky K. Yang
- Department of Clinical SciencesTufts University Cummings School of Veterinary MedicineNorth Grafton Massachusetts USA
- Yijun Yang
- State Key Laboratory of Respiratory DiseaseGuangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesGuangzhou China
- Ronne Wee Yeh Yeo
- Institute of Medical Biology, A*STAR Singapore
- Hang Yin
- Department of Chemistry and Biochemistry and the BioFrontiers InstituteUniversity of Colorado BoulderBoulder Colorado USA
- Bernd Giebel
- Institute for Transfusion Medicine, University Hospital Essen, University Duisburg‐Essen Germany
- Eva Rohde
- Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI‐TReCS), Paracelsus Medical University (PMU)Salzburg Austria
- Sai Kiang Lim
- Institute of Medical Biology, A*STAR Singapore
- DOI
- https://doi.org/10.1002/sctm.17-0055
- Journal volume & issue
-
Vol. 6,
no. 8
pp. 1730 – 1739
Abstract
Abstract Growing interest in extracellular vesicles (EVs, including exosomes and microvesicles) as therapeutic entities, particularly in stem cell‐related approaches, has underlined the need for standardization and coordination of development efforts. Members of the International Society for Extracellular Vesicles and the Society for Clinical Research and Translation of Extracellular Vesicles Singapore convened a Workshop on this topic to discuss the opportunities and challenges associated with development of EV‐based therapeutics at the preclinical and clinical levels. This review outlines topic‐specific action items that, if addressed, will enhance the development of best‐practice models for EV therapies. Stem Cells Translational Medicine 2017;6:1730–1739
Keywords
- Stem cells
- Cellular therapy
- Clinical trials
- Clinical translation
- Extracellular vesicles
- Therapeutics
